- Research Article
- 10.1182/blood-2025-3130
Risk of thrombosis in multiple myeloma patients treated with carfilzomib-based regimens: A systematic review and meta-analysis of clinical trials
- Nov 03, 2025
- Blood
- Prateek Pophali + 5 more +5
Publications from 2021 to 2026
Showing 10 of 90 papers
Risk of thrombosis in multiple myeloma patients treated with carfilzomib-based regimens: A systematic review and meta-analysis of clinical trials
ZERO CORONARY ARTERY CALCIUM SCORE: IMPLICATION OF GENDER
First pass effect as an independent predictor of functional outcomes in medium vessel occlusions: An analysis of an international multicenter study.
First pass effect (FPE), achievement of complete recanalization (mTICI 2c/3) with a single pass, is a significant predictor of favorable outcomes for endovascular treatment (EVT) in large vessel occlusion stroke (LVO). However, data concerning the impact on functional outcomes and predictors of FPE in medium vessel occlusions (MeVO) are scarce. We conducted an international retrospective study on MeVO cases. Multivariable logistic modeling was used to establish independent predictors of FPE. Clinical and safety outcomes were compared between the two study groups (FPE vs non-FPE) using logistic regression models. Good outcome was defined as modified Rankin Scale 0-2 at 3 months. Eight hundred thirty-six patients with a final mTICI ⩾ 2b were included in this analysis. FPE was observed in 302 patients (36.1%). In multivariable analysis, hypertension (aOR 1.55, 95% CI 1.10-2.20) and lower baseline NIHSS score (aOR 0.95, 95% CI 0.93-0.97) were independently associated with an FPE. Good outcomes were more common in the FPE versus non-FPE group (72.8% vs 52.8%), and FPE was independently associated with favorable outcome (aOR 2.20, 95% CI 1.59-3.05). 90-day mortality and intracranial hemorrhage (ICH) were significantly lower in the FPE group, 0.43 (95% CI, 0.25-0.72) and 0.55 (95% CI, 0.39-0.77), respectively. Over 2/3 of patients with MeVOs and FPE in our cohort had a favorable outcome at 90 days. FPE is independently associated with favorable outcomes, it may reduce the risk of any intracranial hemorrhage, and 3-month mortality.
Read moreCharacterization of Emergency Department Poisoning Epidemiology in Belize
Objective: Little is known about the epidemiology of poisonings in Belize. The purpose of this study was to characterize poisonings presenting to Karl Heusner Memorial Hospital, Department of Accident and Emergency in Belize City, Belize. Methods: Charts were reviewed for patients with possible toxicologic exposures, presenting between May 31, 2016 – December 31, 2018. Variables of interest included patient age and sex, type and route of poisoning, reason for exposure, and disposition. Results: Of the 60,310 patient visits during the study period, 768 patients, 1.3%, presented after a toxicologic exposure. The age distribution of poisoned patients varied with the largest proportion being between 19-30 years of age, 29.3%. There was a male predominance of patients, 60.4%. Approximately 44% of all poisonings involved ethanol only. Marijuana was the most common drug of abuse. Other common inhalation and ingested exposures included cleaning agents, household agents, acetaminophen, NSAIDs, pesticides, organophosphates, sedating medications, antibiotics, and ciguatera poisoning. Nearly 48 % of intoxication cases were due to intentional abuse, while about eight percent were from suicide attempts. Of identified poisoned patients, 84.4% were ultimately discharged, 13.8% were admitted, 1.6% were “self-discharged,” 0.13% were transferred, and 0.13% died. Conclusions: This study illustrates that poisoning is an important cause of Accident and Emergency visits in Belize, whose patterns may differ from those in other countries. Understanding the current state of poisonings in Belize can aid in the development of treatment protocols, antidote stocking, and educational activities for poisoning prevention.
Read moreP020 - CHANGES TO PARENTAL CONSENT REQUIREMENTS FOR ABORTION IN MASSACHUSETTS AND IMPACT ON TIMELINESS OF CARE FOR MINORS
O-063 First U.S. multicenter experience using the pipeline flex embolization device with shield technology for treatment of intracranial aneurysms
Introduction/PurposeSince becoming available in 2007, flow diverters introduced the principle of endovascular reconstruction of the parent artery and exclusion of the aneurysm from the blood circulation, which has revolutionized intracranial aneurysm treatment. Despite the overall positive results, a major concern of flow diverter implantation is possible ischemic and thromboembolic complications. To reduce material thrombogenicity, the PED Flex device underwent surface modification with covalently bonded phosphorylcholine to the surface of the implant, so called Shield Technology™. This technology has been shown to reduce thrombogenicity and promote endothelialization with earlier and thicker neointima formation but less hyperplasia.Materials and MethodsProspectively maintained neurointerventional databases at 10 high-volume U.S. medical centers were retrospectively reviewed between April 2021 (corresponding with the FDA approval of the PED Shield) and October 2021. Additionally, compassionate use cases between 2016 and 2020 were also included. All patients who underwent placement of a PED Shield for treatment of a ruptured or unruptured intracranial aneurysm were identified. Patients who underwent re-treatment of an intracranial aneurysm due to failed primary treatment method were also included. Patient demographics, information on aneurysm size, morphology, and location as well as procedural data including device(s) used, adjunctive coiling and/or balloon angioplasty performed, intraprocedural complications, patient angiographic and clinical outcome was collected.ResultsOne hundred eighty patients were included (144 women) with 187 aneurysms. Nineteen aneurysms were ruptured. The patient’s mean age was 57 years (range 14-84 years). Most aneurysms were located along the ICA (n=154), specifically along the ophthalmic segment (n=73), wide-necked (n=154) and saccular in shape (n=114). Mean aneurysm size was 5.8 mm (1.5 - 22.3 mm). PED Shield deployment was technically successful in 177 cases (98.3%). Balloon angioplasty was performed in 24 cases (13.3%). Aneurysm stasis after device deployment was seen in 113 aneurysms (60.4%). No procedure-related major ischemic stroke or neurological death occurred. Transient ischemic attack was seen in 3 patients (1.7%). One patient suffered an intraparenchymal bleed on post-op day 11 and 1 patient had a minor stroke leading to overall permanent neurological morbidity of 1.1%. Three to 6-month follow up was available for 136 patients (75.6%) and showed complete aneurysm occlusion in 58%, near-complete occlusion in 19.9% and partial occlusion in 22.1%. Twelve to 18-month follow up was available for 67 patients (37.2%). Complete occlusion was seen in 53.7%, near complete occlusion in 31% and partial occlusion in 14.9%. In total, up to 18-month follow-up was available for 143 patients (79.4%) and showed complete or near complete occlusion in 79%. Five patients have been retreated thus far (2.8%).ConclusionOur study is the first to report the early experience with the newly FDA-approved PED Flex with Shield technology amongst US centers. Our results are comparable with non-US, international studies showing a high technical success rate and safe peri-procedural angiographic and patient outcome. Longer follow-up will be needed to provide more robust data on angiographic and patient outcomes.DisclosuresA. Kuhn: None. J. Singh: None. A. Abdelsalam: None. V. Saini: None. J. Burks: None. G. Cortez: None. R. Abbas: None. M. Pervez: None. H. Saei: None. S. Burke: None. M. Salem: None. J. Vivanco-Suarez: None. R. Kutcher-Diaz: None. M. Bounajem: None. V. Naragum: None. F. Massari: None. S. Marwah: None. M. Gounis: None. A. Hassan: 1; C; GE Healthcare and Valley Baptist. 2; C; Medtronic, Microvention, Stryker, Penumbra, Cerenovus, Genentech, GE Healthcare, Scientia, Balt, Viz.ai, Insera therapeutics, Proximie, NeuroVasc, NovaSignal, Vesalio, Rapid Medical, Imperative Care a. A. Malek: 2; C; CereVasc Inc.. 4; C; CereVasc Inc. G. Dabus: 2; C; Medtronic, Microvention, Cerenovus, Penumbra, Stryker, InNeuroCo, Route 92. I. Linfante: 2; C; Medtronic, Cerenovus. 4; C; InNeuroCo, Deinde, Prometeous, Three Rivers, Prolong Pharmaceuticals. S. Tjoumakaris: 2; C; Medtronic and Microvention (funds paid to institution, not personally). P. Jabbour: 2; C; Medtronic, Microvention and Cerus. J. Burkhardt: None. B. Jankowitz: None. F. Mudassir: None. S. Ortega Gutierrez: None. R. Grandhi: None. R. Hanel: 1; C; NIH, Interline Endowment, Microvention, Stryker and CNX. 2; C; Medtronic, Balt, Stryker, Q’Apel medical, Codman Neuro (J&J), Cerenovus, Microvention, Imperative Care, Phenox and Rapid Medical. R. Starke: 1; C; NREF, Joe Niekro Foundation, Brain Aneurysm Foundation, Bee Foundation, and by National Institute of Health, Medtronic. 2; C; Penumbra, Abbott, Medtronic, Balt, InNeuroCo, Cerenovus, Naglreiter and Optimize Vascular. A. Puri: 1; C; NIH, Microvention, Cerenovus, Medtronic Neurovascular and Stryker Neurovascular. 2; C; Medtronic Neurovascular, Stryker NeurovascularBalt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical. 4; C; InNeuroCo, Agile, Perfuze, Galaxy and NTI.
Read moreThe effects of aqueous and ethanolic extracts of Rheum ribes on insulin-resistance and apolipoproteins in patients with type 2 diabetes mellitus: a randomized controlled trial
Background and aimPrevious studies have shown that Rheum ribes (R. ribes) could be effective in controlling the blood glucose levels. This study was conducted to determine the effects of R. ribes supplementation on glycemic indices and apolipoproteins in patients with type 2 diabetes mellitus (T2DM).MethodsIn the present randomized double-blind controlled trial, 60 type 2 diabetic patients aged 30–60 years with a body mass index (BMI) of 20–30 kg/m2 and hemoglobin A1c (HbA1c) of 6–8% were enrolled. Patients were randomly assigned to receive 450 mg of aqueous R. ribes extract (AG), 450 mg of ethanolic R. ribes extract (EG), or placebo (PG) three times daily for 6 weeks. At the baseline and at the end of the study, blood glucose levels, homeostatic model assessment of insulin resistance (HOMA-IR) and the homeostatic model assessment of β-cell dysfunction (HOMA-B), as well as apolipoprotein A-I (ApoA1) and apolipoprotein B (ApoB) were measured.ResultsThere was a significant decrease in the serum levels of insulin in AG and EG groups (P = 0.003 and P = 0.001, respectively), HOMA-IR (P = 0.01 and P = 0.001, respectively), HOMA-B (P = 0.002 and P = 0.001, respectively), ApoB (P = 0.006 and P = 0.03, respectively), ApoB/ApoA1 ratio (P = 0.016 and P = 0.04, respectively). However, a significant increase in ApoA1 (P = 0.08 and P = 0.05, respectively) with no significant changes in blood glucose, at the end of study compared to beginning values, were observed. None of the variables showed a significant change in PG. At the end of the study; while there were significant differences in insulin (P = 0.04), HOMA-IR (P = 0.03), HOMA-B (P = 0.01), ApoB (P = 0.02), and ApoB/ApoA1 ratio (P = 0.03) among the groups but ApoA1 had no significant change.ConclusionConsumption of R. ribes intake could have beneficial effects on insulin resistance and apolipoproteins in type 2 diabetic patients. (Registered at en.irct.ir, identification number: IRCT201410142709N31).
Read moreCardio-Obstetrics: the Next Frontier in Cardiovascular Disease Prevention.
Purpose of ReviewInternationally, cardiovascular disease (CVD) is the leading cause of death in women. With risk factors for CVD continuing to rise, early identification and management of chronic diseases such as hypertension, diabetes, and obstructive sleep apnea is necessary for prevention. Pregnancy is a natural stress test for women with risk factors who may be predisposed to CVD and offers a unique opportunity to not only recognize disease but also implement effective and long-lasting strategies for prevention.Recent FindingsPrevention begins before pregnancy, as preconception screening, counseling, and optimization of chronic diseases can improve maternal and fetal outcomes. Throughout pregnancy, women should maintain close follow-up, continued reevaluation of risk factors, with counseling when necessary. Continued healthcare engagement during the “fourth trimester,” 3 months following delivery, allows clinicians to continue monitoring the evolution of chronic diseases, encourage ongoing lifestyle counseling, and connect women with primary care and appropriate specialists if needed. Unfortunately, this postpartum period represents a major care gap, as a significant proportion of most women do not attend their scheduled visits. Social determinants of health including decreased access to care and economic instability lead to increased risk factors throughout pregnancy but particularly play a role in poor compliance with postpartum follow-up. The use of telemedicine clinics and remote monitoring may prove to be effective interventions, bridging the gap between physicians and patients and improving follow-up for at-risk women.SummaryWhile many clinicians are beginning to understand the impact of CVD on women, screening and prevention strategies are not often implemented until much later in life. Pregnancy creates an opportunity to begin engaging women in cardiovascular protective strategies before the development of the disease.
Read moreCan sonographic fetal head circumference measurement help predict obstetric anal sphincter injury?
To investigate whether sonographic fetal head circumference (sfHC) size assessed by ultrasound prenatally could help predict OASIS. This study is a retrospective cohort study between 2005 and 2016. Antenatal sfHC assessment, maternal demographics, and labor and delivery data were abstracted and compared in women with and without OASIS. Of 2057 pregnant women that had sfHC assessment, 121 (5.8%) had OASIS. In the unadjusted analysis, sfHC above the 90th centile was associated with OASIS (odds ratio [OR] 1.12; 95% confidence interval [CI] 1.02-1.23; P=0.015). When adjusted for gestational age at delivery, maternal age, race, prolonged second stage, body mass index, infant gender, and intrapartum oxytocin use, sfHC above the 90th centile remained significantly associated with OASIS (OR 1.13, 95% CI 1.00-1.27, P=0.050). In our cohort, sfHC above the 90th centile was associated with a greater risk of OASIS. As OASIS significantly impacts both short-term and long-term health outcomes, such as perineal pain, dyspareunia, and urinary and fecal incontinence, sfHC could be an additional prenatal marker to help clinicians counsel pregnant women about the risk of OASIS.
Read moreMachine Learning Model Based on Transthoracic Bioimpedance and Heart Rate Variability for Lung Fluid Accumulation Detection: Prospective Clinical Study (Preprint)
BACKGROUND Accumulation of excess body fluid and autonomic dysregulation are clinically important characteristics of acute decompensated heart failure. We hypothesized that transthoracic bioimpedance, a noninvasive, simple method for measuring fluid retention in lungs, and heart rate variability, an assessment of autonomic function, can be used for detection of fluid accumulation in patients with acute decompensated heart failure. OBJECTIVE We aimed to evaluate the performance of transthoracic bioimpedance and heart rate variability parameters obtained using a fluid accumulation vest with carbon black–polydimethylsiloxane dry electrodes in a prospective clinical study (System for Heart Failure Identification Using an External Lung Fluid Device; SHIELD). METHODS We computed 15 parameters: 8 were calculated from the model to fit Cole-Cole plots from transthoracic bioimpedance measurements (extracellular, intracellular, intracellular-extracellular difference, and intracellular-extracellular parallel circuit resistances as well as fitting error, resonance frequency, tissue heterogeneity, and cellular membrane capacitance), and 7 were based on linear (mean heart rate, low-frequency components of heart rate variability, high-frequency components of heart rate variability, normalized low-frequency components of heart rate variability, normalized high-frequency components of heart rate variability) and nonlinear (principal dynamic mode index of sympathetic function, and principal dynamic mode index of parasympathetic function) analysis of heart rate variability. We compared the values of these parameters between 3 participant data sets: control (n=32, patients who did not have heart failure), baseline (n=23, patients with acute decompensated heart failure taken at the time of admittance to the hospital), and discharge (n=17, patients with acute decompensated heart failure taken at the time of discharge from hospital). We used several machine learning approaches to classify participants with fluid accumulation (baseline) and without fluid accumulation (control and discharge), termed <i>with fluid and without fluid</i> groups, respectively. RESULTS Among the 15 parameters, 3 transthoracic bioimpedance (extracellular resistance, R<sub>0</sub>; difference in extracellular-intracellular resistance, R<sub>0</sub> – R<sub>∞</sub>, and tissue heterogeneity, α) and 3 heart rate variability (high-frequency, normalized low-frequency, and normalized high-frequency components) parameters were found to be the most discriminatory between groups (patients with and patients without heart failure). R<sub>0</sub> and R<sub>0</sub> – R<sub>∞</sub> had significantly lower values for patients with heart failure than for those without heart failure (R<sub>0</sub>: <i>P</i>=.006; R<sub>0</sub> – R<sub>∞</sub>: <i>P</i>=.001), indicating that a higher volume of fluids accumulated in the lungs of patients with heart failure. A cubic support vector machine model using the 5 parameters achieved an accuracy of 92% for with fluid and without fluid group classification. The transthoracic bioimpedance parameters were related to intra- and extracellular fluid, whereas the heart rate variability parameters were mostly related to sympathetic activation. CONCLUSIONS This is useful, for instance, for an in-home diagnostic wearable to detect fluid accumulation. Results suggest that fluid accumulation, and subsequently acute decompensated heart failure detection, could be performed using transthoracic bioimpedance and heart rate variability measurements acquired with a wearable vest.
Read more